Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

Sinus infections, also known as sinusitis, can leave us feeling miserable with symptoms like nasal congestion, facial pain ...

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Dec 15 (Reuters) - UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved pharma major GSK’s Exdensur (depemokimab), the first twice-yearly biological medicine for use as an add-on treatment for ...

Cantor Fitzgerald raised the firm’s price target on Insmed (INSM) to $230 from $216 and keeps an Overweight rating on the shares. The firm views ...

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

The 2025 AAO‐HNSF adult sinusitis guideline, an update of the 2015 guideline, offers evidence-based recommendations on rhinosinusitis management.

Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has ...